Literature DB >> 22116660

bFGF interaction and in vivo angiogenesis inhibition by self-assembling sulfonic acid-based copolymers.

L García-Fernández1, M R Aguilar, L Ochoa-Callejero, C Abradelo, A Martínez, J San Román.   

Abstract

The antiangiogenic activity of different families of biocompatible and non-toxic polymer drugs based on 2-acrylamido-2-methylpropane sulfonic acid (AMPS) or polymethacrylic derivatives of 5-aminonaphthalen sulfonic acid (MANSA) is analyzed using directed in vivo angiogenesis assay and correlated with in vitro results. These active compounds were copolymerized with butylacrylate (BA) and N-vinylpyrrolidone in order to obtain two families of copolymers with different properties in aqueous media. The most hydrophobic copolymers poly(BA-co-MANSA) and poly(BA-co-AMPS) formed amphiphilic copolymers and presented micellar morphology in aqueous media. This supramolecular organization of the copolymers had a clear effect on bioactivity. Poly(BA-co-MANSA) copolymers showed the best antiangiogenic activity and very low toxicity at relatively low dose, with the possibility to be injected directly in the solid tumors alone or in combination with other therapeutic agents such as anti-VEGF drugs. The obtained results demonstrate that not only the chemical structure but also the supramolecular organization of the macromolecules plays a key role in the anti-angiogenic activity of these active polymers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116660     DOI: 10.1007/s10856-011-4497-y

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  29 in total

1.  The role of fibroblast growth factors in vascular development.

Authors:  Sophie Javerzat; Patrick Auguste; Andreas Bikfalvi
Journal:  Trends Mol Med       Date:  2002-10       Impact factor: 11.951

Review 2.  The therapeutic potential of novel antiangiogenic therapies.

Authors:  Frank A Scappaticci
Journal:  Expert Opin Investig Drugs       Date:  2003-06       Impact factor: 6.206

Review 3.  Angiogenic and angiostatic factors in the molecular control of angiogenesis.

Authors:  J H W Distler; A Hirth; M Kurowska-Stolarska; R E Gay; S Gay; O Distler
Journal:  Q J Nucl Med       Date:  2003-09

4.  Rapid measurement of binding constants and heats of binding using a new titration calorimeter.

Authors:  T Wiseman; S Williston; J F Brandts; L N Lin
Journal:  Anal Biochem       Date:  1989-05-15       Impact factor: 3.365

5.  Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.

Authors:  Israel S Fernández; Pedro Cuevas; Javier Angulo; Pilar López-Navajas; Angeles Canales-Mayordomo; Rocío González-Corrochano; Rosa M Lozano; Serafín Valverde; Jesús Jiménez-Barbero; Antonio Romero; Guillermo Giménez-Gallego
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

Review 6.  Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

Authors:  Robert J Ignoffo
Journal:  Am J Health Syst Pharm       Date:  2004-11-01       Impact factor: 2.637

7.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

8.  Chlorpheniramine binding to human serum albumin by fluorescence quenching measurements.

Authors:  J Gonzalez-Jimenez; G Frutos; I Cayre; M Cortijo
Journal:  Biochimie       Date:  1991-05       Impact factor: 4.079

Review 9.  Antiangiogenesis, anti-VEGF(R) and outlook.

Authors:  Iver Petersen
Journal:  Recent Results Cancer Res       Date:  2007

Review 10.  Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Authors:  Patrizia Alessi; Daria Leali; Maura Camozzi; Annarita Cantelmo; Adriana Albini; Marco Presta
Journal:  Eur Cytokine Netw       Date:  2009-12       Impact factor: 2.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.